Invesco Ltd. Sells 20,709 Shares of Krystal Biotech, Inc. $KRYS

Key Points

• Invesco Ltd. reduced its stake in Krystal Biotech by 7.5%, owning approximately 254,486 shares after selling 20,709 shares in the first quarter.
• Fifth Third Bancorp and GAMMA Investing LLC significantly increased their stakes in Krystal Biotech by 159.1% and 179.3%, respectively, during the same period, indicating heightened interest from other institutional investors.
• Krystal Biotech reported an earnings per share (EPS) of $1.29, surpassing estimates, and maintaining a strong outlook with a consensus price target of $210.75 from analysts.

Invesco Ltd. lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 254,486 shares of the company's stock after selling 20,709 shares during the quarter. Invesco Ltd. owned about 0.88% of Krystal Biotech worth $45,884,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Crossmark Global Holdings Inc. increased its holdings in shares of Krystal Biotech by 2.7% in the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock worth $427,000 after purchasing an additional 63 shares during the period. Summit Investment Advisors Inc. increased its holdings in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock worth $407,000 after purchasing an additional 82 shares during the period. Xponance Inc. increased its holdings in shares of Krystal Biotech by 4.9% in the first quarter. Xponance Inc. now owns 1,873 shares of the company's stock worth $338,000 after purchasing an additional 88 shares during the period. Sound View Wealth Advisors Group LLC increased its holdings in shares of Krystal Biotech by 6.7% in the first quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock worth $273,000 after purchasing an additional 95 shares during the period. Finally, New York State Teachers Retirement System increased its holdings in shares of Krystal Biotech by 0.6% in the first quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock worth $2,881,000 after purchasing an additional 100 shares during the period. Institutional investors own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 49,800 shares of company stock valued at $7,487,943 over the last ninety days. 13.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on KRYS. Citigroup reaffirmed a "neutral" rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Chardan Capital cut their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday. Bank of America cut their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. HC Wainwright reiterated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Friday. Finally, Guggenheim cut their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $210.38.

Krystal Biotech Price Performance

NASDAQ KRYS traded up $3.4450 during trading on Friday, hitting $149.1450. 21,240 shares of the company's stock traded hands, compared to its average volume of 329,377. The stock has a fifty day moving average of $143.96 and a two-hundred day moving average of $154.67. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84. The firm has a market cap of $4.32 billion, a P/E ratio of 30.39 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).